Shi-Yi Wang, MD, PhD

2026

• Potential benefits and harms of screening strategies for monoclonal gammopathy of undetermined significance in the US: A simulation study

  Ahmad I, Wang R, Neparidze N, Lange J, Wang S. Potential benefits and harms of screening strategies for monoclonal gammopathy of undetermined significance in the US: A simulation study. Clinical Lymphoma Myeloma & Leukemia 2026 DOI: 10.1016/j.clml.2026.06.001.

  Peer-Reviewed Original Research

• Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma.

  Wang R, Ji M, Neparidze N, Ma X, Chang S, Wang S. Immunomodulatory Agent Adherence Trajectories and Survival Among Older Patients With Multiple Myeloma. JCO Oncology Practice 2026, op2500615. PMID: 42081788, DOI: 10.1200/op-25-00615.

  Peer-Reviewed Original Research

  Altmetric

• Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States

  Lee D, Li Y, Yang S, Chiang A, Soulos P, Gross C, Wang S. Treatment Patterns Across Lines of Therapy for Advanced Non‐Small Cell Lung Cancer in the United States. Cancer Medicine 2026, 15: e71736. PMID: 42007970, PMCID: PMC13094514, DOI: 10.1002/cam4.71736.

  Peer-Reviewed Original Research

  Altmetric

  MeSH Keywords

• QIM26-284: Practice-Level Variation in ECOG Performance Status Documentation in Advanced Non–Small Cell Lung Cancer

  Li Y, Wang S, Zhang Y, Yang S, Lee D, Soulos P, Wang X, Gross C, Chiang A. QIM26-284: Practice-Level Variation in ECOG Performance Status Documentation in Advanced Non–Small Cell Lung Cancer. Journal Of The National Comprehensive Cancer Network 2026, 24 DOI: 10.6004/jnccn.2025.7441.

  Peer-Reviewed Original Research

• Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population

  Wang M, Sigel B, Liu L, Huber J, Ji M, Schoen M, Sanfilippo K, Thomas T, Colditz G, Hsu S, Wang S, Chang S. Quantifying the contribution of modifiable risk factors for progression of MGUS to multiple myeloma in a Veteran population. International Journal Of Cancer 2026, 159: 618-628. PMID: 41813601, PMCID: PMC13004480, DOI: 10.1002/ijc.70412.

  Peer-Reviewed Original Research

  Altmetric

• The association between body fatness and prevalent MGUS in the U.S. general population

  Ji M, Huber J, Wang M, Lan T, Colditz G, Wang S, Chang S. The association between body fatness and prevalent MGUS in the U.S. general population. Cancer Epidemiology 2026, 101: 103021. PMID: 41702266, PMCID: PMC13081065, DOI: 10.1016/j.canep.2026.103021.

  Peer-Reviewed Original Research

  Citations

  MeSH Keywords

• A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling

  Wang X, Long J, Rothen J, Huang S, Soulos P, Goldberg S, Robinson T, Ma S, Mamtani R, Presley C, Wang S, Kunst N, Gross C, Dinan M. A Taxonomy for Assessing Real-World Targeted Cancer Therapy Options in the Context of Broad Genomic Profiling. Journal Of The National Comprehensive Cancer Network 2026, 24: e257131. PMID: 41698347, PMCID: PMC13112471, DOI: 10.6004/jnccn.2025.7131.

  Peer-Reviewed Original Research

  This study introduces Y-MATRIX, a taxonomy classifying genomic profiling results by clinical actionability, showing increased actionable findings in advanced lung cancer from 2017 to 2023.

  Full Summary

• Overestimation of multiple myeloma survival from cancer registry data

  Huber J, Wang M, Wang R, Schoen M, Colditz G, Wang S, Chang S. Overestimation of multiple myeloma survival from cancer registry data. Journal Of The National Cancer Institute 2026, djag028. PMID: 41652897, PMCID: PMC12967285, DOI: 10.1093/jnci/djag028.

  Peer-Reviewed Original Research

  Altmetric

• Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States.

  Leapman M, Long J, Westvold S, Rabil M, Sprenkle P, Kim I, Spilberg G, Saperstein L, Fallah J, Suzman D, Lerro C, Xu J, Rivera D, Kluetz P, Karnes R, Dinan M, Mitchell A, Kunst N, Wang S, Ma X, Gross C. Adoption and Regional Variation of Prostate-Specific Membrane Antigen Positron Emission Tomography in the United States. JCO Oncology Practice 2026, op2500617. PMID: 41632928, DOI: 10.1200/op-25-00617.

  Peer-Reviewed Original Research

  This study investigates the rapid adoption of PSMA-PET imaging for prostate cancer in the U.S., highlighting increased usage since 2021 and disparities based on income and education.

  Full Summary

• Smoldering multiple myeloma in the United States: a population-based analysis

  Wang S, Wang R, Schoen M, Huber J, Feuer E, Ruhl J, Neparidze N, Ma X, Davidoff A, Chang S. Smoldering multiple myeloma in the United States: a population-based analysis. Blood Advances 2026, 10: 661-664. PMID: 41213002, PMCID: PMC12870838, DOI: 10.1182/bloodadvances.2025017817.

  Peer-Reviewed Original Research

  Altmetric